Fierce Biotech January 7, 2025
Gabrielle Masson, Darren Incorvaia

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry.

We’re maintaining the criteria we used for last year’s tracker, which means including financing rounds north of $50 million. Of course, we’ll still profile innovative new companies and larger rounds in-depth, while we focus more coverage on clinical trial results, M&A and special reports.

January

Jan. 6—Orbis Medicines
Series: A
Amount: €90 million (About $93.4 million)
Investors: NEA (New Enterprise Associates), Eli Lilly, Cormorant, the Export and Investment Fund of Denmark, and founding...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
CVS Caremark taps Omada on GLP-1 program
InnovationRx: Trump Administration Health Agency Layoffs Threaten Biotech Innovation
Which Biopharma Startups Made the Cut for INVEST Pitch Perfect?
PBMs push private-label biosimilars in 2025 formularies

Share This Article